TRIDENT LIFELINE
|
The Current P/E Ratio of TRIDENT LIFELINE is 35.80.
Share Price | ₹249.5 | Mar 12,2025 |
Market Cap | ₹286.9 Cr | |
Earnings-TTM | ₹8.0 Cr | TTM-Consolidated Results |
Price/Earnings | 35.80x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of TRIDENT LIFELINE
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹286.9 Cr] as on Mar 12,2025
(/) Earnings [ ₹8.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 35.80x ]
Thus, for TRIDENT LIFELINE , the investors are currently willing to pay 35.80 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of TRIDENT LIFELINE !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of TRIDENT LIFELINE over the last five years.
Historical PE (Price/Earnings) ratio chart of TRIDENT LIFELINE
PE Ratio Performance Analysis for TRIDENT LIFELINE
- TRIDENT LIFELINE 's p/e ratio for fiscal years ending Mar2024 to Mar2022 averaged 20.04x.
- TRIDENT LIFELINE 's operated at median p/e ratio of 29.71x from fiscal years ending March 2018 to 2022.
- Looking back at the last 3 fiscal years, TRIDENT LIFELINE 's p/e ratio peaked in Mar2023 at 30.41x.
- TRIDENT LIFELINE 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does TRIDENT LIFELINE 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
TRIDENT LIFELINE | 8.01 | 35.80 | 286.9 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,486.00 | 35.02 | 402,213.0 |
DIVIS LABORATORIES LTD | 2,067.00 | 72.76 | 150,403.0 |
CIPLA LTD | 5,000.43 | 23.48 | 117,415.0 |
TORRENT PHARMACEUTICALS LTD | 1,862.00 | 56.28 | 104,791.0 |
DR REDDYS LABORATORIES LTD | 5,428.60 | 16.99 | 92,228.2 |
MANKIND PHARMA LTD | 2,050.73 | 43.65 | 89,504.8 |
ZYDUS LIFESCIENCES LTD | 4,591.80 | 19.48 | 89,454.2 |
LUPIN LTD | 2,892.10 | 31.02 | 89,719.4 |
AUROBINDO PHARMA LTD | 3,500.25 | 18.37 | 64,288.9 |
ABBOTT INDIA LTD | 1,334.46 | 47.49 | 63,371.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs TRIDENT LIFELINE 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 16.99x |
Max industry PE | 72.76x |
Median industry PE | 35.02x |
Average industry PE | 36.39x |
You may also like the below Video Courses